OC
SPRO icon

Oppenheimer & Co’s Spero Therapeutics SPRO Stock Holding History

Oppenheimer & Co’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.5K Buy
+22,850
New +$59.8K ﹤0.01% 1740

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Oppenheimer & Co's SPRO Position: Q2 2026 in Review

Oppenheimer & Co opened a new position in Spero Therapeutics (SPRO) in Q2 2026: 22,850 shares worth $50.5K. The stake represents ﹤0.01% of the portfolio and ranks #1740 among its holdings.

60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • Oppenheimer & Co held 22,850 shares of Spero Therapeutics worth $50.5K as of Q2 2026.
  • Spero Therapeutics was a new Oppenheimer & Co position in Q2 2026.
  • Spero Therapeutics made up ﹤0.01% of Oppenheimer & Co's portfolio in Q2 2026, its #1740 holding.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.